PARTNERRE LTD

PRE

Does Prenetics Global Limited (PRE) have what it takes to be a top stock pick for momentum investors? Let's find out.

Prenetics Global Limited is transitioning from diagnostics to a health sciences company, driven by strong IM8 supplement sales and recent asset divestitures. PRE's revenue is surging, with IM8 projected to reach $100M in annual recurring revenue and perhaps become profitable in Q1 2026. The stock is rated a cautious Buy due to growth potential, though risks include Bitcoin investments, volatile share price, and dependence on IM8's momentum.

Launch Follows IM8's Record Growth to $6.6 Million Monthly Revenue in September IM8 Accelerates Toward $100 Million ARR Milestone with One of the Industry's Fastest Growth Rates CHARLOTTE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, today announced the launch of Daily Ultimate Longevity from its rapidly scaling IM8 Health brand co-founded by David Beckham.

- Keynote: “IM8: The World's Fastest-Growing Supplement Brand Powering Our Bitcoin Treasury - Prenetics currently holds 246 BTC with a NAV of $28M - Prenetics has $63.5m of cash 1 CHARLOTTE, N.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics”), a leading consumer health sciences company, today announced Chief Executive Officer, Danny Yeung will deliver a keynote address at Token 2049, one of the world's premier crypto and blockchain conferences, taking place in Singapore.

Does Prenetics Global Limited (PRE) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 st Half revenue grew 452.1% to $32.3 million YoY IM8 achieved $5.9 million revenue in August 2025, representing a CAGR 1 of over 3,100% Prenetics increases FY2025 revenue guidance range of $85 – $100 million Prenetics provides update on Bitcoin Treasury, adding a total of 228 Bitcoin, and accumulating 1 BTC daily Prenetics to achieve break-even in Q1 2026, and EBITDA positive moving forward CHARLOTTE, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced unaudited financial results for the second quarter ended June 30, 2025, along with recent business updates.

CHARLOTTE, N.C., June 26, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, announced today at a special event at Wimbledon House that IM8, its premium supplements brand co-founded by David Beckham, has partnered with world No. 1 tennis star Aryna Sabalenka as its newest global ambassador and shareholder. The announcement comes just days before the start of Wimbledon on June 30th, where Sabalenka will be competing as one of the tournament favorites.

-  Prenetics adopts proven corporate Bitcoin strategy inspired by MicroStrategy's ~$40B Bitcoin holdings and Metaplanet's meteoric treasury transformation

CHARLOTTE, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics”), a leading consumer health sciences company, today announced it has entered into a definitive agreement to divest its ownership in ACT Genomics Holdings Company Limited (“ACT Genomics”) to Delta Electronics, Inc. (TWSE: 2308) (“Delta”). Delta is a global leader in power management and smart green solutions, as well as a provider of healthcare technologies. The transaction regarding Delta's acquisition of up to 100% ACT Genomics' shareholdings is valued at up to US$71.78 million. Prenetics, holding a majority stake in ACT Genomics, will receive a gross proceed of approximately US$46 million in cash post-closing of the transaction and subject to customary release conditions. With a cash balance of US$44 million1, this divestment bolsters Prenetics financial position, increasing its pro-forma cash reserves to approximately US$86 million2 and with $117 million pro-forma short term assets3, while maintaining a debt-free balance sheet.

Adds Renowned Clinical Experts Dr. Jeremy London and Dr. Amy Shah to Existing Team from Mayo Clinic, Cedars-Sinai, NASA and Yale University